AmyriAD Therapeutics B.V.
Privately held: no public share price · Netherlands
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Undisclosed / early pipeline | Schizophrenia Cognitive Impairment Associated with Schizophrenia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
25 July 2025Topline resultInidascamine (RL-007)Phase 2b CIAS topline: inidascamine missed the primary endpoint
Recognify Life Sciences · Source ↗
Financial reports
No financial reports recorded.